House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Oncology

Spinal metastases and metastatic spinal cord compression

NICE · 2023 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

A focused clinical pathway for suspected or established spinal metastases and metastatic spinal cord compression (MSCC), including recognition, urgent imaging, corticosteroids, local treatment and rehabilitation. The guidance also applies to direct malignant spinal infiltration. Decisions about surgery and radiotherapy require coordinated oncology, spinal and radiology assessment, with the person’s priorities and overall condition included.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Recognise an oncological emergency

  • In a person with past or current cancer, bladder or bowel dysfunction, gait disturbance, limb weakness, sensory change, radicular pain or other cord/cauda-equina signs require immediate contact with the MSCC coordinator: treat suspected cord compression as an oncological emergency. [1]
  • For past or current cancer with back pain suggestive of metastases—such as progressive, severe unremitting, mechanical or sleep-disturbing night pain—seek MSCC advice within 24 hours. If these suggestive back-pain characteristics are present, cancer is suspected and there is no established cancer history, arrange urgent oncology assessment. [1]
  • Begin immobilisation immediately, including during transfer, for suspected or confirmed MSCC with neurological features suggesting instability. Consider immobilisation for movement-related moderate or severe pain; obtain expert stability advice within 24 hours to avoid unnecessarily prolonged immobilisation. [1]

Image the spine promptly

  • For suspected MSCC, obtain MRI as soon as possible and always within 24 hours, preferably locally; transfer for MRI only when local imaging is impossible. Suspected spinal metastases without suspected MSCC require MRI within 1 week. [1]
  • Spinal MRI should cover the whole spine with sagittal T1 and/or STIR, include sagittal T2 to assess cord or cauda-equina compression, and add axial images through significant abnormalities. Do not perform surveillance MRI solely to detect early cord compression in asymptomatic established spinal metastases. [1]
  • If MRI is contraindicated, use CT; occasionally myelography after CT is needed, and it belongs in a neuroscience or spinal surgical centre. Plain spinal X-rays cannot be used to diagnose or exclude spinal metastases or MSCC. [1]

Use corticosteroids with the correct population

  • For neurological symptoms or signs of MSCC, give oral dexamethasone 16 mg, or an equivalent parenteral dose, as soon as possible; continue 16 mg daily while awaiting surgery or radiotherapy. Taper after surgery or when radiotherapy starts, following glucocorticoid-withdrawal guidance. [1]
  • If dexamethasone was started before imaging and both spinal metastases and MSCC are excluded, discontinue it. For disease without effective treatment options, taper to stop; continue only if symptoms recur or worsen during reduction. [1]
  • Without neurological features, do not routinely start corticosteroids, except as part of radiotherapy; consider them for severe pain or haematological malignancy. For radiologically suspected lymphoma or myeloma with spinal metastases but no neurological signs, obtain haematology advice before starting steroids. [1]
  • For confirmed haematological malignancy with spinal metastases, with or without neurological features, offer dexamethasone 16 mg orally or equivalent parenterally promptly. Agree subsequent steroid treatment with the haematology multidisciplinary team. [1]
  • During corticosteroid treatment, monitor blood glucose, offer proton-pump-inhibitor acid suppression, and follow adrenal-insufficiency guidance when withdrawing glucocorticoids. [1]

Choose radiotherapy with its exceptions

  • For MSCC unsuitable for spinal surgery, offer urgent radiotherapy as soon as possible and within 24 hours, unless complete tetraplegia/paraplegia has lasted at least 2 weeks with well-controlled pain, or overall prognosis is poor. [1]
  • For MSCC treated with radiotherapy, use a single 8 Gy fraction unless side-effect risk is high. Consider multiple fractions for high-risk situations such as large fields or previous irradiation. [1]
  • For spinal metastases without MSCC causing non-mechanical pain, offer single-fraction 8 Gy radiotherapy, including when paralysed. Consider stereotactic ablative radiotherapy for good overall prognosis or oligometastatic disease with up to 3 discrete metastases and spinal involvement. [1]
  • For asymptomatic spinal metastases, consider radiotherapy only within a prevention trial, as part of treatment for oligometastases (up to 3 discrete metastases anywhere in the body) with spinal involvement, or for radiological impending cord compression from epidural or intradural tumour. [1]
  • Offer postoperative radiotherapy after recovery from surgery for spinal metastases or MSCC. Before irradiating haematological spinal disease when stem-cell harvest is contemplated, discuss the potential effect on harvest with the haematology team. [1]

Assess stability and surgical options

  • Plan invasive treatment with the specialist multidisciplinary team. When the primary cancer is unknown, obtain an image-guided biopsy if the result may change treatment and immediate treatment is not required. [1]
  • Offer surgery intended to halt or reverse MSCC neurological decline as soon as possible after neurological onset; urgency depends on onset speed and progression. Duration of complete paralysis alone must not determine whether restorative surgery is offered. [1]
  • For MSCC with instability and mechanical pain uncontrolled by analgesia, offer stabilisation surgery if suitable, even with potentially irreversible severe neurological deficit. If surgery is unsuitable, offer external spinal support. [1]
  • Consider validated stability and prognostic scores alongside clinical assessment. Scores support, rather than replace, evaluation of health, pain, imaging and relevant prognostic factors when discussing treatment. [1]

Support pain, movement and recovery

  • If assessment and imaging suggest stability, test graded sitting then weight bearing while monitoring pain and neurology. Progress only without orthostatic hypotension, significant pain increase or neurological deterioration; if symptoms worsen, return to a position that reverses them and reassess stability. [1]
  • Provide pain relief promptly, including while awaiting investigations. Offer rehabilitation from diagnosis according to ongoing needs and personal goals, and begin discharge and continuing-care planning at hospital admission. [1]

Limitations and use

  • This focused pathway does not reproduce every analgesic, bone-targeted treatment, invasive technique or re-irradiation recommendation. Specialist assessment remains necessary for treatment selection and dosing beyond the regimens explicitly described.
  • Referral roles and service organisation are written for the UK; local equivalents and urgent imaging, oncology and spinal-surgery access must be identified for use in India.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Spinal metastases and metastatic spinal cord compression

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
NICE
First published
6 September 2023
Resource type
Clinical guideline · House clinical summary
Source setting
United Kingdom

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Recognise an oncological emergency
  • Image the spine promptly
  • Use corticosteroids with the correct population
  • Choose radiotherapy with its exceptions
  • Assess stability and surgical options
  • Support pain, movement and recovery
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House